- Home
- SOFI vs ROIV Comparison
SOFI vs ROIV Comparison
Compare SOFI & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOFI
- ROIV
- Stock Information
- Founded
- SOFI 2011
- ROIV 2014
- Country
- SOFI United States
- ROIV United Kingdom
- Employees
- SOFI N/A
- ROIV N/A
- Industry
- SOFI Diversified Financial Services
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- SOFI Finance
- ROIV Health Care
- Exchange
- SOFI Nasdaq
- ROIV Nasdaq
- Market Cap
- SOFI 25.4B
- ROIV 8.6B
- IPO Year
- SOFI N/A
- ROIV N/A
- Fundamental
- Price
- SOFI $27.67
- ROIV $13.95
- Analyst Decision
- SOFI Hold
- ROIV Strong Buy
- Analyst Count
- SOFI 16
- ROIV 4
- Target Price
- SOFI $18.67
- ROIV $15.50
- AVG Volume (30 Days)
- SOFI 68.1M
- ROIV 6.7M
- Earning Date
- SOFI 10-28-2025
- ROIV 11-11-2025
- Dividend Yield
- SOFI N/A
- ROIV N/A
- EPS Growth
- SOFI N/A
- ROIV N/A
- EPS
- SOFI 0.49
- ROIV N/A
- Revenue
- SOFI $3,029,346,000.00
- ROIV $23,233,000.00
- Revenue This Year
- SOFI $31.59
- ROIV N/A
- Revenue Next Year
- SOFI $23.49
- ROIV $281.14
- P/E Ratio
- SOFI $56.58
- ROIV N/A
- Revenue Growth
- SOFI 29.27
- ROIV N/A
- 52 Week Low
- SOFI $7.57
- ROIV $8.73
- 52 Week High
- SOFI $27.76
- ROIV $14.48
- Technical
- Relative Strength Index (RSI)
- SOFI 69.25
- ROIV 73.22
- Support Level
- SOFI $25.30
- ROIV $11.85
- Resistance Level
- SOFI $26.86
- ROIV $14.48
- Average True Range (ATR)
- SOFI 1.14
- ROIV 0.42
- MACD
- SOFI 0.04
- ROIV 0.19
- Stochastic Oscillator
- SOFI 97.54
- ROIV 81.61
About SOFI SoFi Technologies Inc.
SoFi is a financial-services company that was founded in 2011 and is based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020, the company also offers payment and account services for debit cards and digital banking.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.